SavedAdd your journal

Journals / Türk Dermatoloji Dergisi / 2019 / Cilt: 13 - Sayı: 2

Quality of Life in Turkish Patients with Autoimmune Blistering Diseases: Reliability and Validity of the Autoimmune Bullous Disease Quality of Life and the Treatment of Autoimmune Bullous Disease Quality of Life Questionnaires

Aslı TEMEL BİLGİÇ
Ceren İRİCAN
Soner UZUN
Grant Y. H. FENG
Dedee F. MURRELL
Ayşe AKMAN KARAKAŞ
Pages
27–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

They canbe used to measure treatment burden in Turkish AIBD patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment of Autoimmune Bullous Disease Qualityof Life (TABQOL) questionnaires, which are specific for autoimmune blistering diseases (AIBDs), were developed in Australia.Aims and Objectives: The aim of this study was to validate the Turkish version of the ABQOL and TABQOL questionnaires and to assess thereliability of them in the Turkish population.
📊
Key Findings & Data:The patients were requested to complete ABQOL and TABQOLquestionnaires on day 0 and after 7 days for a 2nd time sent by post.
💡
Conclusion & Impact:They canbe used to measure treatment burden in Turkish AIBD patients.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: The Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment of Autoimmune Bullous Disease Qualityof Life (TABQOL) questionnaires, which are specific for autoimmune blistering diseases (AIBDs), were developed in Australia.Aims and Objectives: The aim of this study was to validate the Turkish version of the ABQOL and TABQOL questionnaires and to assess thereliability of them in the Turkish population. Materials and Methods: The Turkish versions of the ABQOL and TABQOL questionnaires wereproduced by forward–backward translation of the original English version. The patients were requested to complete ABQOL and TABQOLquestionnaires on day 0 and after 7 days for a 2nd time sent by post. Furthermore, patients also completed other health‑related quality of lifescales on day 0. Results: A total of 68 patients with AIBDs were recruited. A subset of 20 (29.4%) patients completed the day 7 questionnaire.Both the Turkish versions of the ABQOL and TABQOL questionnaires had a high internal consistency (0.86 and 0.88, respectively) and test–retest reliability (0.87 and 0.87, respectively). The correlation between ABQOL and TABQOL scores was moderate (Pearson’s R = 0.609).Conclusion: We have shown that the Turkish versions of ABQOL and TABQOL questionnaires are valid and reliable instruments. They canbe used to measure treatment burden in Turkish AIBD patients.

🔖

Cite This Article

BİLGİÇ, A. T., İRİCAN, C., UZUN, S., FENG, G. Y. H., MURRELL, D. F., KARAKAŞ, A. A. (2019). Quality of Life in Turkish Patients with Autoimmune Blistering Diseases: Reliability and Validity of the Autoimmune Bullous Disease Quality of Life and the Treatment of Autoimmune Bullous Disease Quality of Life Questionnaires. Türk Dermatoloji Dergisi, Cilt: 13 - Sayı: 2, 27–34. https://ajindex.com/articles/417159

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Alpsoy E, Akman‑Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: Pemphigus and bullous pemphigoid. Arch Dermatol Res 2015;307:291‑8
  2. Yayli S, Harman M, Baskan EB, Karakas AA, Genc Y, Turk BG, et al. Epidemiology of pemphigus in Turkey: One‑year prospective study of 220 cases. Acta Dermatovenerol Croat 2017;25:181‑8
  3. Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol 2010;49:768‑74
  4. Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16‑year retrospective study (1980‑1995). Int J Dermatol 2000;39:104‑8
  5. V’lckova‑Laskoska MT, Laskoski DS, Kamberova S, Caca‑Biljanovska N, Volckova N. Epidemiology of pemphigus in Macedonia: A 15‑year retrospective study (1990‑2004). Int J Dermatol 2007;46:253‑8
  6. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 2012;30:78‑83
  7. Sebaratnam DF, Hanna AM, Chee SN, Frew JW, Venugopal SS, Daniel BS, et al. Development of a quality‑of‑life instrument for autoimmune bullous disease: The autoimmune bullous disease quality of life questionnaire. JAMA Dermatol 2013;149:1186‑91
  8. Tjokrowidjaja A, Daniel BS, Frew JW, Sebaratnam DF, Hanna AM, Chee S, et al. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol 2013;169:1000‑6
  9. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043‑6
  10. Oztürkcan S, Ermertcan AT, Eser E, Sahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol 2006;45:1300‑7
  11. Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med 1979;9:139‑45
  12. Ozdemir H, Rezaki M. General health questionnaire‑12 for the detection of depression. Turk Psikiyatri Derg 2007;18:13‑21
  13. Kilic C, Rezaki M, Rezaki B, Kaplan I, Ozgen G, Sağduyu A, et al. General health questionnaire (GHQ12and & GHQ28): Psychometric properties and factor structure of the scales in a Turkish primary care sample. Soc Psychiatry Psychiatr Epidemiol 1997;32:327‑31